Evotec SE
EVO3.130USD
-0.010-0.32%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.11BMarket Cap
LossP/E TTM
More Details of Evotec SE Company
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Evotec SE Info
Ticker SymbolEVO
Company nameEvotec SE
IPO dateOct 11, 1999
CEOWojczewski (Christian)
Number of employees4827
Security typeDepository Receipt
Fiscal year-endOct 11
AddressEssener Bogen 7
CityHAMBURG
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryGermany
Postal code22419
Phone4940560810
Websitehttps://www.evotec.com/
Ticker SymbolEVO
IPO dateOct 11, 1999
CEOWojczewski (Christian)
Company Executives of Evotec SE
Name
Name/Position
Position
Shareholding
Change
Prof. Dr. Iris Loewfriedrich
Prof. Dr. Iris Loewfriedrich
Independent Chairwoman of the Supervisory Board
Independent Chairwoman of the Supervisory Board
--
--
Mr. Volker Braun
Mr. Volker Braun
Senior Vice President, Head of Global Investor Relations and ESG
Senior Vice President, Head of Global Investor Relations and ESG
--
--
Mr. Wesley Wheeler
Mr. Wesley Wheeler
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Christian Wojczewski
Dr. Christian Wojczewski
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Duncan Mchale
Dr. Duncan Mchale
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Ms. Camilla Macapili Languille
Ms. Camilla Macapili Languille
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Constanze Ulmer-Eilfort
Dr. Constanze Ulmer-Eilfort
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mrs. Aurelie Dalbiez
Mrs. Aurelie Dalbiez
Chief People Officer, Member of the Management Board
Chief People Officer, Member of the Management Board
--
--
Dr. Cord Dohrmann, Ph.D.
Dr. Cord Dohrmann, Ph.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
Ms. Laetitia Rouxel
Ms. Laetitia Rouxel
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Prof. Dr. Iris Loewfriedrich
Prof. Dr. Iris Loewfriedrich
Independent Chairwoman of the Supervisory Board
Independent Chairwoman of the Supervisory Board
--
--
Mr. Volker Braun
Mr. Volker Braun
Senior Vice President, Head of Global Investor Relations and ESG
Senior Vice President, Head of Global Investor Relations and ESG
--
--
Mr. Wesley Wheeler
Mr. Wesley Wheeler
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Christian Wojczewski
Dr. Christian Wojczewski
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Duncan Mchale
Dr. Duncan Mchale
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Ms. Camilla Macapili Languille
Ms. Camilla Macapili Languille
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
482.23M
55.94%
Switzerland
117.94M
13.68%
United Kingdom
100.06M
11.61%
Rest of the world
89.00M
10.32%
Germany
35.59M
4.13%
Other
37.16M
4.31%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Mubadala Investment Company PJSC
1.29%
Wellington Management Company, LLP
0.40%
BlackRock Institutional Trust Company, N.A.
0.36%
DCF Advisers, LLC
0.34%
WCM Investment Management
0.08%
Other
97.52%
Shareholders
Shareholders
Proportion
Mubadala Investment Company PJSC
1.29%
Wellington Management Company, LLP
0.40%
BlackRock Institutional Trust Company, N.A.
0.36%
DCF Advisers, LLC
0.34%
WCM Investment Management
0.08%
Other
97.52%
Shareholder Types
Shareholders
Proportion
Sovereign Wealth Fund
1.29%
Investment Advisor
0.94%
Investment Advisor/Hedge Fund
0.42%
Family Office
0.05%
Hedge Fund
0.04%
Research Firm
0.01%
Other
97.24%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
76
9.39M
2.97%
--
2025Q3
77
9.39M
2.97%
-16.64K
2025Q2
74
9.40M
2.85%
+334.04K
2025Q1
60
9.08M
2.82%
-923.30K
2024Q4
59
8.93M
2.90%
+634.42K
2024Q3
56
8.37M
3.36%
+770.57K
2024Q2
55
7.62M
2.73%
+2.19M
2024Q1
54
5.00M
2.98%
-5.56M
2023Q4
57
5.71M
1.76%
+4.47M
2023Q3
51
1.23M
1.80%
-162.10K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Mubadala Investment Company PJSC
4.60M
1.29%
--
--
Jun 30, 2025
Wellington Management Company, LLP
1.21M
0.34%
-697.85K
-36.66%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.32M
0.37%
-184.93K
-12.32%
Jun 30, 2025
DCF Advisers, LLC
1.11M
0.31%
+362.91K
+48.29%
Jun 30, 2025
WCM Investment Management
297.91K
0.08%
+297.91K
--
Jun 30, 2025
Parametric Portfolio Associates LLC
303.50K
0.09%
+303.50K
--
Jun 30, 2025
Pitcairn
261.18K
0.07%
+261.18K
--
Jun 30, 2025
Citadel Advisors LLC
33.57K
0.01%
+33.57K
--
Jun 30, 2025
LPL Financial LLC
37.84K
0.01%
+37.84K
--
Jun 30, 2025
Envestnet Asset Management, Inc.
91.66K
0.03%
+91.66K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Biotechnology ETF
0.08%
ActivePassive International Equity ETF
0%
DFA Dimensional Intl Sustainability Core 1 ETF
0%
iShares Biotechnology ETF
Proportion0.08%
ActivePassive International Equity ETF
Proportion0%
DFA Dimensional Intl Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Evotec SE?
The top five shareholders of Evotec SE are:
Mubadala Investment Company PJSC holds 4.60M shares, accounting for 1.29% of the total shares.
Wellington Management Company, LLP holds 1.21M shares, accounting for 0.34% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.32M shares, accounting for 0.37% of the total shares.
DCF Advisers, LLC holds 1.11M shares, accounting for 0.31% of the total shares.
WCM Investment Management holds 297.91K shares, accounting for 0.08% of the total shares.
Mubadala Investment Company PJSC holds 4.60M shares, accounting for 1.29% of the total shares.
Wellington Management Company, LLP holds 1.21M shares, accounting for 0.34% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.32M shares, accounting for 0.37% of the total shares.
DCF Advisers, LLC holds 1.11M shares, accounting for 0.31% of the total shares.
WCM Investment Management holds 297.91K shares, accounting for 0.08% of the total shares.
What are the top three shareholder types of Evotec SE?
The top three shareholder types of Evotec SE are:
Mubadala Investment Company PJSC
Wellington Management Company, LLP
BlackRock Institutional Trust Company, N.A.
Mubadala Investment Company PJSC
Wellington Management Company, LLP
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Evotec SE (EVO)?
As of 2025Q4, 76 institutions hold shares of Evotec SE, with a combined market value of approximately 9.39M, accounting for 2.97% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.00%.
What is the biggest source of revenue for Evotec SE?
In FY2024, the -- business generated the highest revenue for Evotec SE, amounting to -- and accounting for --% of total revenue.
